Compare · AXSM vs ODT
AXSM vs ODT
Side-by-side comparison of Axsome Therapeutics Inc. (AXSM) and Odonate Therapeutics Inc. (ODT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. AXSM focuses on Biotechnology: Pharmaceutical Preparations, while ODT focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- AXSM is the larger of the two at $12.68B, about 294.1x ODT ($43.1M).
- AXSM has hit the wire 23 times in the past 4 weeks while ODT has been quiet.
- AXSM has more recent analyst coverage (25 ratings vs 0 for ODT).
- Company
- Axsome Therapeutics Inc.
- Odonate Therapeutics Inc.
- Price
- $252.47+2.51%
- $1.12-4.27%
- Market cap
- $12.68B
- $43.1M
- 1M return
- +12.78%
- -
- 1Y return
- +133.61%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2017
- News (4w)
- 23
- 0
- Recent ratings
- 25
- 0
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Odonate Therapeutics Inc.
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Latest AXSM
- Director Saad Mark E converted options into 1,429 shares, increasing direct ownership by 14% to 11,431 units (SEC Form 4)
- Director Jeffs Roger converted options into 1,429 shares, increasing direct ownership by 2% to 58,939 units (SEC Form 4)
- Director Mahony Susan converted options into 1,429 shares and sold $145,017 worth of shares (600 units at $241.69) as part of a pre-agreed trading plan (SEC Form 4)
- Director Coleman Mark converted options into 1,429 shares and sold $160,107 worth of shares (643 units at $249.00) as part of a pre-agreed trading plan, increasing direct ownership by 3% to 30,389 units (SEC Form 4)
- SEC Form 144 filed by Axsome Therapeutics Inc.
- SEC Form 144 filed by Axsome Therapeutics Inc.
- SEC Form 144 filed by Axsome Therapeutics Inc.
- Axsome Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Axsome Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 4 filed by Director Coleman Mark
Latest ODT
- SEC Form 25-NSE filed by Odonate Therapeutics Inc.
- 60 Biggest Movers From Yesterday
- 56 Biggest Movers From Friday
- Odonate Therapeutics shares are trading lower after the company received notice from The Nasdaq Stock Market that the continued listing of its securities is no longer warranted.
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Stocks That Hit 52-Week Lows On Friday
- Odonate Therapeutics Announces Expected Delisting Of Stock
- Odonate Therapeutics, Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Odonate Announces Expected Delisting of Its Stock
- Stocks That Hit 52-Week Lows On Thursday